Form 4: Fennec Pharmaceuticals CFO Robert Andrade Reports Share Acquisition
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on July 31, 2024.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, reported a transaction on July 31, 2024.
- Andrade acquired 1,042 common shares of Fennec Pharmaceuticals at a price of $0.
- Following the transaction, Andrade beneficially owns 108,439 common shares.
- The shares were released from restriction from shares awarded 3-31-2023.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard regulatory filing reporting a share transaction. The acquisition itself could be seen as slightly positive, but the filing is primarily informational.
Positives
- The acquisition of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of compliance for company insiders and provide transparency into their transactions in the company's stock.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment due to the CFO's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 2023-03-31 | Date of original share award. |
| 2024-07-31 | Date of transaction: acquisition of 1,042 common shares. |
| 2024-08-01 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.